Inhibition of Cytochrome P450 Activities by Sophora flavescens Extract and Its Prenylated Flavonoids in Human Liver Microsomes
Autor: | Daeun Yim, Jae-Gook Shin, Yumi Shin, Dong-Hyun Kim, Su-Jun Lee, Min-Jung Kim |
---|---|
Rok vydání: | 2019 |
Předmět: |
Sophora flavescens
Article Subject CYP2B6 CYP3A4 biology Chemistry CYP3A Cytochrome P450 lcsh:Other systems of medicine Pharmacology lcsh:RZ201-999 biology.organism_classification 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Complementary and alternative medicine 030220 oncology & carcinogenesis biology.protein Microsome CYP2C8 CYP2C9 Research Article |
Zdroj: | Evidence-based Complementary and Alternative Medicine : eCAM Evidence-Based Complementary and Alternative Medicine, Vol 2019 (2019) |
ISSN: | 1741-4288 1741-427X |
DOI: | 10.1155/2019/2673769 |
Popis: | Sophora flavescens possesses several pharmacological properties and has been widely used for the treatment of diarrhea, inflammation, abscess, dysentery, and fever in East Asian countries. S. flavescens is a major source of prenylated flavonoids, such as sophoraflavone and kushenol. In this study, we examined the effects of S. flavescens extract and its prenylated flavonoids on cytochrome P450 (CYP) isoform activity in human liver microsomes. The extract inhibited CYP2C8, CYP2C9, CYP2C19, and CYP3A activities, with IC50 values of 1.42, 13.6, 19.1, and 50 µg/mL, respectively. CYP2B6 was only inhibited in human liver microsomes preincubated with the extract. CYP3A4 was more strongly inhibited by the extract in the presence of NADPH, suggesting that the extract may inhibit CYP2B6 and CYP3A4 via mechanism-based inactivation. Prenylated flavonoids also inhibited CYP isoforms with different selectivity and modes of action. Kushenol I, leachianone A, and sophoraflavone G inhibited CYP2B6, whereas kushenol C, kushenol I, kushenol M, leachianone A, and sophoraflavone G inhibited CYP3A4 via mechanism-based inhibition. Our results suggest that S. flavescens may contribute to herb–drug interactions when coadministered with drugs metabolized by CYP2B6, CYP2C8, CYP2C9, and CYP3A4. |
Databáze: | OpenAIRE |
Externí odkaz: |